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Abstract
 
Matrix metalloproteinase (MMP)9/gelatinase B is increased in various nephropathies. To in-
vestigate its role, we used a genetic approach. Adult MMP9-deficient (MMP9
 
2
 
/
 
2
 
) mice
 
showed normal renal histology and function at 3 mo. We investigated the susceptibility of
3-mo-old mice to the accelerated model of anti-glomerular basement membrane nephritis, in
which fibrin is an important mediator of glomerular injury and renal impairment. Unexpect-
edly, nephritis was more severe in MMP9
 
2
 
/
 
2
 
 than in control mice, as attested by levels of se-
rum creatinine and albuminuria, and the extent of crescents and fibrin deposits. Circulating or
deposited immunoglobulin G, interleukin (IL)-1
 
b
 
, or IL-10 were the same in MMP9
 
2
 
/
 
2
 
 and
MMP9
 
1
 
/
 
1
 
 mice. However, we found that fibrin is a critical substrate for MMP9, and in its ab-
sence fibrin accumulated in the glomeruli. These data indicate that MMP9 is required for a
novel protective effect on the development of fibrin-induced glomerular lesions.
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Introduction
 
Matrix metalloproteinase (MMP)
 
1 
 
9/gelatinase B has a re-
stricted pattern of expression in developmental and adult
tissues (for reviews, see references 1 and 2). It is expressed
at the first step of renal development, in the mesenchyme
of 11-d embryonic kidneys (3). This enzyme is required for
kidney maturation in vitro since blocking MMP9 activity
with specific antibodies or its natural inhibitor, the tissue
inhibitor of metalloproteinase (TIMP)1, inhibits kidney
branching morphogenesis and growth (3). In the adult kid-
ney, MMP9 is mainly expressed in glomerular visceral epi-
thelial cells and in collecting duct cells (4, 5), and its ex-
pression is increased in a variety of human renal diseases
and in animal models of nephropathies such as membra-
nous nephropathy, polycystic kidney disease, and renal fi-
brosis (reference 6; for a review, see reference 7).
We took advantage of the availability of MMP9-defi-
cient (MMP9
 
2
 
/
 
2
 
) mice (8) to investigate the renal pheno-
type of these mice and their susceptibility to anti-glomeru-
lar basement membrane (GBM) nephritis, a murine model
of crescentic proliferative glomerulonephritis. We com-
pared the accelerated model of anti-GBM nephritis in
MMP9
 
2
 
/
 
2
 
 mice and MMP9
 
1
 
/
 
1
 
 control mice bred on the
same genetic background. This model is characterized by a
rapid development of severe crescentic proliferative glom-
erulonephritis in which fibrin is an important mediator of
glomerular injury and renal impairment (9). We expected
that MMP9 deficiency would have a protective effect since
MMP9 can degrade almost all GBM components (for a re-
view, see reference 1), thus favoring the issue of fibrin in
the urinary space of the glomerulus. On the contrary, renal
disease was more severe in MMP9
 
2
 
/
 
2
 
 mice than in their
control mates. In particular, the extent of crescent forma-
tion and fibrin deposition was greater, which led us to
show a novel effect of MMP9 on fibrin degradation.
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MMP9-deficient Mice Phenotype and MMP9 Fibrinolytic Activity
 
Materials and Methods
 
Mice.
 
MMP9
 
2
 
/
 
2
 
 
 
129SV mice were generated as described
previously (8) and were used after eight backcrosses to C57BL/6
background. Control MMP9
 
1
 
/
 
1
 
 mice were also obtained by
backcrossing
 
 
 
1
 
/
 
2 
 
129SV mice with wild-type C57BL/6 mice.
Mouse studies followed the Institutional Animal Care and Use
Guidelines. Renal phenotype was compared at 1, 3, 6, and 12
mo. 15 MMP9
 
2
 
/
 
2
 
 and 15 MMP9
 
1
 
/
 
1
 
 female mice were used at
each time point.
 
Antibodies and Reagents.
 
Sheep preimmune serum and sheep
anti-rat GBM serum were supplied by B. Fouqueray (Hôpital
Tenon) in our laboratory (10). Mac-1 and F4/80 hybridomas
were provided by R. Monteiro (Institut National de la Santé et
de la Recherche Médicale U25, Paris, France). Rabbit polyclonal
anti–IL-1
 
b
 
 was obtained from Endogen. Biotinylated mouse
anti–rat antibodies were purchased from The Jackson Immu-
noResearch Laboratories, affinity purified rabbit anti–mouse IgG
conjugated to FITC or peroxidase, rabbit anti–sheep IgG conju-
gated to FITC, and goat anti–rat fibrin IgG conjugated to FITC
were obtained from Biosys. Goat anti–rabbit IgGs conjugated to
alkaline phosphatase were purchased from Amersham Pharmacia
Biotech. Recombinant mouse IL-1
 
b
 
 was obtained from Sigma-
Aldrich. Recombinant mouse MMP9 and human recombinant
TIMP1 were a gift from G. Murphy, University of East Anglia,
Norwich, UK (11) and P. Zaoui, Centre Hospitalies Universi-
taire, Grenoble, France (3), respectively. Fibrin was prepared
from human plasma provided by E. Verdy (Hôpital Tenon). Hu-
man cryodessicated fibrinogen was purchased from Clottagen and
mouse IL-10 ELISA kit from Biosource International.
 
Induction of Glomerulonephritis.
 
For induction of glomerulo-
nephritis, three sets of 10 MMP9
 
2
 
/
 
2
 
 and 10 MMP9
 
1
 
/
 
1
 
 3-mo-old
female mice were sensitized by intraperitoneal injection of 200
 
m
 
g of sheep preimmune serum in the same volume of Freund’s
Complete Adjuvant (Sigma-Aldrich), followed by intravenous
injection of 200 
 
m
 
l of sheep anti-GBM serum 7 d later. To avoid
anaphylactic reaction, mice received an intraperitoneal injection
of 100 
 
m
 
l of anti-GBM serum 1 h before the intravenous injec-
tion. They were studied 24 h and 15 d after anti-GBM injection.
 
Antibody Response.
 
Circulating mouse IgGs directed against
injected sheep anti-GBM antibody were measured by ELISA as
described previously (12) in the sera of 11 MMP9
 
2
 
/
 
2
 
 and 11
MMP9
 
 
 
1
 
/
 
1
 
 female mice collected 24 h and 15 d after anti-GBM
injection. In brief, Costar 96-well plates were coated overnight
with 1 
 
m
 
g/well of sheep IgG, washed, and blocked with 2%
BSA. Then, wells were incubated for 3 h with dilutions of mouse
serum followed by species-specific rabbit anti–mouse IgG conju-
gated to peroxidase for 2 h at a dilution of 1:2,000. Peroxidase
was revealed by 
 
O
 
-phenylenediamine for 1 h, and absorbance
was read at 450 nm on a Titertek Multiskan MCC/340 (Lab-
system Group). Serum from each mouse was tested in serial dilu-
tions from 1:25 to 1:10,000, with serum from five nonimmu-
nized mice used as negative controls.
GBM deposits of injected sheep anti-GBM antibody or of
mouse IgGs directed against injected sheep antibody were as-
sessed by immunofluorescence on 3-
 
m
 
m kidney cryosections
fixed in acetone for 4 min at 4
 
8
 
C. Binding was detected after a
30-min incubation with species-specific FITC-conjugated anti–
sheep or anti–mouse IgG diluted 1:400, respectively.
 
Assessment of Renal Function and Proteinuria.
 
Mice were placed
for 48 h in metabolic cages and urine was collected for the last
24 h. During this time, they were supplied with food and tap wa-
ter ad libitum. Serum and urine creatinine (alkaline picric acid
method) and urine total proteins (Biuret method) were measured
 
on an autoanalyzer (Instrumentation Laboratory). Urine albumin
levels were determined after electrophoresis of total proteins on
Paragon gels (Beckman Coulter) followed by scanning on a Mul-
tiscan RC (Labsystem Group).
 
Assessment of Glomerular Injury.
 
Renal tissue was fixed in Du-
bosq-Brazil’s fixative, embedded in paraffin, cut into 3-
 
m
 
m sec-
tions, and stained with periodic acid-Schiff (PAS) stain and Mas-
son’s Trichrome for histological analysis. Crescent formation
(defined as the presence of three or more layers of cells in Bow-
man’s space) and fibrin deposition were determined on 100
glomeruli/kidney. 11 MMP9
 
2
 
/
 
2
 
 and 11 MMP9
 
1
 
/
 
1
 
 female mice
killed 15 d after anti-GBM injection were used for these studies.
Fibrin deposition was also detected by immunofluorescence
on cryosections fixed with acetone and incubated for 30 min
with FITC-conjugated goat anti–rat fibrin IgG (1 
 
m
 
g/ml).
For detection of macrophages, 3-
 
m
 
m acetone-fixed kidney
cryosections were stained using a three-layer immunoperoxidase
technique. Number of macrophages was determined on 30 glom-
eruli/kidney. Kidney sections were obtained from five MMP9
 
2/2
 
and five MMP9
 
1
 
/
 
1
 
 mice. They were washed in PBS, and endog-
enous avidin and biotin were saturated using an avidin-biotin
blocking kit (Vector Laboratories). Sections were incubated for
30 min with the rat monoclonal anti–mouse macrophage Mac-1
(CD11b) or F4/80 followed for 30 min by a biotinylated mouse
anti–rat IgG (4 
 
m
 
g/ml in PBS supplemented with 2% normal
mouse serum). Avidin-biotin horseradish peroxidase complex
(ABC reagent; Vector Laboratories) was then added for 30 min
and peroxidase was revealed by 3-amino-9-ethyl carbazole for 15
min. Sections were counterstained with hematoxylin for 1 min.
 
Measurement of IL-10 Production.
 
Glomeruli were isolated
from six MMP9
 
1
 
/
 
1
 
 and six MMP9
 
2
 
/
 
2
 
 female mice (killed 48 h,
7 d, and 15 d after anti-GBM injection) and from the same num-
ber of noninjected (
 
1
 
/
 
1
 
) and (
 
2
 
/
 
2
 
) mice. Isolation was per-
formed by graded sieving through no. 150, 106, and 75 meshes as
described previously (13). 10
 
4
 
/ml glomeruli were maintained in
RPMI 1640 supplemented with 1% FCS and 1% penicillin/strep-
tomycin for 24 h (37
 
8
 
C, 5% CO
 
2
 
). Supernatants were collected
and IL-10 was measured by ELISA using a polyclonal antibody
derived against the entire IL-10 protein (Biosource Interna-
tional). The detection limit of the assay was 13 pg/ml. Results
were normalized to total protein in glomerular lysate measured
by protein assay (Bio-Rad Laboratories) or to 1,000 glomeruli.
 
Analysis of IL-1
 
b
 
 Degradation.
 
Isolated glomeruli from 11
MMP9
 
1
 
/
 
1
 
 and 11 MMP9
 
2
 
/
 
2
 
 female mice killed 15 d after anti-
GBM injection were directly lysed in SDS-PAGE sample buffer
(50 mM Tris, 1% SDS, 5% glycerol, 0.002% bromophenol blue).
100 ng recombinant mouse IL-1
 
b
 
 incubated or not with 150 ng
activated recombinant mouse MMP9 for 1 h at 37
 
8
 
C, and 100 
 
m
 
g
of glomerular lysate total protein were submitted to SDS-PAGE
under reducing conditions in a 15% polyacrylamide gel and elec-
tro transferred to nitrocellulose (Schleicher & Schuell) for 2 h at a
constant current of 190 mA. Afterwards, nitrocellulose sheet was
saturated with 5% dry milk in 0.1% PBS-Tween for 1 h at 37
 
8
 
C,
extensively washed in 0.1% PBS-Tween, and incubated overnight
at 4
 
8
 
C with rabbit anti–mouse IL-1
 
b
 
 IgG (4 
 
m
 
g/ml) or rabbit
anti–mouse IL-1
 
b
 
 IgG preincubated with a 50
 
3
 
 excess of recom-
binant mouse IL-1
 
b
 
 as control. Nitrocellulose was then incubated
for 2 h at room temperature with goat anti–rabbit IgG conjugated
to alkaline phosphatase (0.02 
 
m
 
g/ml; Amersham Pharmacia Bio-
tech). Alkaline phosphatase activity was revealed by adding the
NBT/BCI substrate (nitroblue tetrazolium/5-bromo-4-chloro-
3-indolyl phosphate complex in 100 mM Tris-HCl, 100 mM 
795
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NaCl, and 5 mM MgCl
 
2
 
, pH 9.5). The reaction was stopped in
20 mM Tris-HCl, 5 mM EDTA, pH 8.0. Blots were analyzed
with NIH Image 1.61 and converted to a graphical format.
 
Characterization of Fibrinolytic Effect of MMP9.
 
The fibrinolytic
activity of MMP9 was demonstrated by fibrin zymography, by
SDS-PAGE analysis of fibrinogen, and fibrin digestion products in
the presence of MMP9, and by degradation of fibrin deposits in
situ.
For zymographic analysis, recombinant mouse MMP9 (11)
was preactivated with 1 mM 4-aminophenylmercuric acetate
(Sigma-Aldrich) at 37
 
8
 
C for 3 h and different quantities (300,
150, and 50 ng) were loaded onto 8% SDS polyacrylamide gels
(Merck). Electrophoresis was performed under nonreducing con-
ditions at 20 mA. Gels were washed twice for 30 min in 2.5%
Triton X-100 to remove SDS and applied to a fibrin gel (50 mg
of human fibrinogen, 4 U of thrombin, 10 
 
m
 
l of 10% Triton
X-100 per gel) performed in gelatinase substrate buffer (50 mM
Tris-HCl, 5 mM CaCl
 
2
 
, 1 
 
m
 
M ZnCl
 
2
 
, 0.01% NaN
 
3
 
, pH 7.5) for
48 h at 37
 
8
 
C. The MMP9 fibrinolytic activity was detected by a
proteolytic band in the fibrin gel. In some experiments, metallo-
proteinase inhibitors (10 
 
m
 
g/ml of recombinant human TIMP1)
were supplied in the fibrin gel.
For fibrin and fibrinogen degradation studies, 10
 
 m
 
g of human
fibrinogen was dissolved in 20 
 
m
 
l gelatinase substrate buffer, then
incubated for 24 h at 37
 
8
 
C with 300 ng activated recombinant
mouse MMP9. Fibrinogen degradation by plasmin was assessed
by incubating 10 
 
m
 
g of human fibrinogen for 24 h at 37
 
8
 
C with
10 mU of plasmin. Control experiments included omission of ac-
tivated recombinant mouse MMP9 or plasmin and addition of a
metalloproteinase inhibitor (1 mM 1,10-phenanthroline) or of a
plasmin inhibitor (8 U aprotinin). Fibrinogen degradation was
then estimated after electrophoresis on 8% SDS polyacrylamide
gels under reducing conditions. Gels were stained with 0.5%
Coomassie blue. Fibrin was prepared from human plasma accord-
ing to the technique of Schwartz et al. (14). In brief, human
plasma was incubated with thrombin (vol/vol; 1,000 U/ml
thrombin) for 2 h at room temperature, then rinsed in PBS for
48 h at 4
 
8
 
C. The 3-
 
m
 
g fibrin pellet was incubated with activated
recombinant mouse MMP9 (300 ng diluted in 5 
 
m
 
l gelatinase
substrate buffer) for 72 h at 37
 
8
 
C. Control experiments included
omission of activated recombinant mouse MMP9, addition of a
metalloproteinase inhibitor (1 mM 1,10-phenanthroline) or of a
plasmin inhibitor (8 U aprotinin) to the gelatinase buffer. The fi-
brin pellet was then solubilized in 25 
 
m
 
l urea buffer (9 M urea,
3% SDS, 3% mercaptoethanol in 0.04 M sodium phosphate
buffer, pH 7.1) for 12 h at 37
 
8
 
C, and loaded on 6% SDS poly-
acrylamide gels under reducing conditions. Gels were stained
with 0.5% Coomassie blue.
For
 
 
 
in situ
 
 
 
fibrin degradation studies, serial 3-mm kidney sec-
tions cut from frozen tissue obtained from three MMP92/2 mice
(killed 15 d after anti-GBM injection) were incubated with acti-
vated recombinant mouse MMP9 (300, 150, and 50 ng) for 24 h
at 378C. In a second set of experiments designed to demonstrate
MMP9 fibrinolytic activity in vivo, serial sections of kidney were
incubated for 72 h at 378C with glomerular extracts obtained
from MMP91/1 mice killed 15 d after anti-GBM injection and
treated with a plasmin inhibitor (1,000 U/ml aprotinin). Control
experiments included omission of glomerular extracts, addition of
a metalloprotease inhibitor (1 mM 1,10 phenanthroline) and a
plasmin inhibitor to glomerular extracts obtained from MMP91/1
mice, and use of glomerular extracts obtained from MMP92/2
mice killed 15 d after anti-GBM injection and treated with a plas-
min inhibitor. Negative immunofluorescent control was obtained
by incubating the section with untreated glomerular extracts ob-
tained from MMP91/1 mice. Fibrin deposits on glomerular sec-
tions were detected by immunofluorescence as described above.
Statistics. Results are expressed as mean 6 SEM. Significan-
ces of differences between MMP92/2 and MMP91/1 mice were
determined by analysis of variance (ANOVA).
Results
MMP9 Deficiency Decreases Renal Function and Increases
Proteinuria in Mice with Anti-GBM Nephritis. We used
2–3-mo-old MMP92/2 mice and their age-matched
MMP91/1 mates to induce the accelerated model of anti-
GBM glomerulonephritis. At 3 mo of age, the function and
histology of the MMP92/2 kidneys were not different from
MMP91/1 kidneys (data not shown), as described previ-
ously (15).
Figure 1. Effect of MMP9 deficiency on renal function in anti-GBM
glomerulonephritis. (A) Serum creatinine (Creat.), protein (Prot.), and al-
bumin (Alb.) levels in MMP91/1 (hatched bars) and MMP92/2 (white
bars) mice. n = 25. (B) Urinary parameters. Urine was collected for 24 h
from MMP91/1 (hatched bars) and MMP92/2 (white bars) mice housed
in metabolic cages, and results were expressed as the ratio of albumin to
creatinine (Alb./Creat.) or as daily proteinuria (Prot./day). Sera and urine
were collected 15 d after injection of anti-GBM antibody. Values in non-
injected MMP91/1 mice were: albumin/creatinine = 10.23 6 0.97; pro-
teinuria/day = 4.01 6 2.16. Values in noninjected MMP92/2 mice were
almost identical to control MMP91/1 mice: albumin/creatinine = 9.76 6
1.02; proteinuria/day = 4.21 6 1.36. Values are mean 6 SEM; *P ,
0.02, **P , 0.01 versus MMP91/1 control mice. n = 15.796 MMP9-deficient Mice Phenotype and MMP9 Fibrinolytic Activity
We observed no significant difference in renal function
and histological features between MMP92/2 and MMP91/1
mice at the heterologous phase that occurs 24 h after the
injection of sheep anti-GBM antibody (data not shown). At
the autologous phase, 15 d after the injection of the anti-
GBM antibody, both control and MMP92/2 mice devel-
oped a crescentic proliferative glomerulonephritis. Surpris-
ingly, the renal failure was more severe in MMP92/2 mice
(Fig. 1 A). These mice also showed a markedly increased
urinary protein loss, expressed as albumin over creatinine
ratio or daily proteinuria, compared with MMP91/1 mates
(Fig. 1 B). However, serum total proteins and serum albu-
min did not differ between the two groups.
MMP9 Deficiency Aggravates Histological Features of Anti-
GBM Nephritis. Decreased renal function in MMP92/2
versus control mice was attributable to increased severity of
lesions. Both MMP92/2 and MMP91/1 mice developed
proliferative glomerulonephritis but glomerular lesions
were more severe in MMP92/2 mice as shown by the
greater extent of fibrin deposits by immunofluorescent
staining (compare Fig. 2 B with A and Fig. 3 A). Fibrin
could also be observed in paraffin-embedded sections
stained with PAS (Fig. 2 E). Crescent formation was mod-
erate in MMP91/1 kidneys and involved only 6% of glom-
eruli (Fig. 3 A). Crescents were larger in MMP92/2 kid-
neys and were observed in z50% of glomeruli (Fig. 3 A).
However, the number of intraglomerular, periglomerular,
and total macrophages was not significantly increased in
MMP92/2 compared with MMP91/1 kidneys (Fig. 3 B).
Kidneys from MMP92/2 mice also showed numerous di-
lated tubules filled with casts which were not observed in
control MMP91/1 mice (compare Fig. 2 D with C). These
casts apparently contained proteins or red blood cells attest-
ing to the severity of glomerular disease.
MMP9 Deficiency Does Not Alter Immune Parameters, IL-
1b, or IL-10. Since the extent of immune response to
sheep anti-GBM antibody is important in determining the
severity of injury in this model of glomerulonephritis, we
Figure 2. Photomicrographs of representative kidney
sections from mice with anti-GBM nephritis 15 d after anti-
GBM injection. (A and B) Fibrin deposition in glomeruli of
(A) MMP91/1 and (B) MMP92/2 mice assessed by immu-
nofluorescence of cryostat frozen sections with antifibrin an-
tibody. Intense glomerular fibrin deposits were observed in
MMP92/2 kidney sections where they affected most of the
glomeruli. Fibrin deposits were weaker and segmental in
most glomeruli from MMP91/1 mice. Bar, 70 mm. (C–E)
Paraffin kidney sections from (C) MMP91/1 and (D and E)
MMP92/2 mice stained with (C and D) Masson’s
Trichrome or (E) PAS. Note numerous dilated tubules
filled with proteinaceous and red blood cells containing casts
in MMP92/2 kidneys, contrasting with the lack of tubule
lesions in control MMP91/1 kidneys. A representative
glomerulus from an MMP92/2 kidney is shown in E. Note
an extensive crescent in the left half of the glomerulus and
massive fibrin deposition mainly in the right half, with rup-
ture of the Bowman’s capsule (arrow). Such severe glomer-
ular lesions were unusually observed in MMP91/1 control
kidneys. Bar: (C and D) 170 mm; (E) 40 mm.797 Lelongt et al.
measured circulating levels of mouse anti–sheep IgG anti-
bodies. Antibody titers, measured by ELISA at dilution of
sera from 1:25 to 1:10,000, were not significantly different
for MMP92/2 mice compared with their (1/1) control
group. Results obtained at a serum dilution of 1:200 are
shown in Fig. 4 A. We then used immunofluorescence to
evaluate whether the greater severity of the nephritis in
MMP92/2 mice could result from larger amounts of im-
mune deposits. We observed no difference in GBM depo-
sition of injected sheep anti-GBM antibody (Fig. 4, B and
C), or mouse anti–sheep IgG (Fig. 4, D and E) in MMP91/1
(Fig. 4, B and D) compared with MMP92/2 (Fig. 4, C and
E) mice.
The proinflammatory cytokine IL-1b plays an important
role in the development of glomerular lesions observed in
anti-GBM nephritis (16) and can be degraded in vitro by
metalloproteases (17). We next investigated whether defec-
tive IL-1b degradation could contribute to the severity of
renal lesions observed in MMP92/2 mice. We used a rabbit
polyclonal antibody directed against the entire protein
which recognized a single band at the expected molecular
size (17.5 kD) in Western blot analysis performed with re-
Figure 3. Glomerular fibrin deposition, crescent formation, and glomer-
ular macrophages 15 d after anti-GBM injection. (A) The percentages of
glomeruli with crescent or fibrin deposition in MMP91/1 (hatched bars)
and MMP92/2 (white bars) kidneys were evaluated on Masson’s
Trichrome (fibrin) and PAS (crescent) stains of paraffin sections. They
were determined on 100 glomeruli per kidney; 11 kidneys were examined.
Values are mean 6 SEM; **P , 0.01, ***P , 0.001 versus MMP91/1
control mice. (B) Numbers of intraglomerular (intra), periglomerular
(peri), and total (tot) macrophages per glomerulus in MMP91/1 (hatched
bars) and MMP92/2 (white bars) mice were counted after staining the
macrophages with F4/80 antibody as described in Materials and Methods.
They were determined on 30 glomeruli per kidney; five kidneys were ex-
amined. Values are mean 6 SEM. No statistical difference was observed.
Figure 4. Assessment of immune response. (A) Evaluation of antibody
production to injected sheep anti-GBM antibody by ELISA. Mouse anti–
sheep IgG antibody was measured in sera of MMP91/1 (hatched bars) and
MMP92/2 (white bars) mice 24 h and 15 d after injection of the anti-
body. n = 11. Serum dilutions ranged from 1:25 to 1:10,000. The serum
dilution shown on this graph is 1:200. MMP92/2 mice exhibited slightly
lower absorbance values that were not statistically significant. (B–E) Esti-
mation of antibody deposition by immunofluorescence 15 d after injec-
tion of the antibody. Deposition of injected (B and C) sheep anti-GBM
antibody or (D and E) mouse anti–sheep IgG was compared in (B and D)
MMP91/1 and (C and E) MMP92/2 mice. A similar intensity of fluores-
cence was observed in MMP92/2 and control mice. Bar, 70 mm.798 MMP9-deficient Mice Phenotype and MMP9 Fibrinolytic Activity
combinant mouse IL-1b (Fig. 5 A, middle). We verified
that IL-1b could be cleaved in vitro by MMP9, leading to
a degradation product of 14.5 kD (Fig. 5 A, middle). We
further checked the specificity of these bands, which disap-
peared when the membrane was incubated with the appro-
priate control (polyclonal antibody preincubated with an
excess of IL-1b) (Fig. 5 A, right). We did not observe any
difference in the amounts of the intact (17.5 kD) and the
degraded forms (14.5 kD) of IL-1b in isolated glomeruli
from both MMP92/2 and MMP91/1 mice (Fig. 5 A, left,
and B).
We also measured IL-10, an antiinflammatory cytokine
that plays a protective role in this model (18), because IL-
10 production was shown to be reduced in a model of skin
contact hypersensitivity in MMP92/2 mice (19). IL-10
production was increased in both groups of mice 48 h, 7 d,
and 15 d after anti-GBM injection compared with their re-
spective noninjected controls (Fig. 5 C). IL-10 normalized
to total protein in glomerular lysate (data not shown) or to
1,000 glomeruli (Fig. 5 C) was similar in MMP92/2 and
MMP91/1 glomeruli 48 h, 7 d, and 15 d after anti-GBM
injection.
MMP9 Is a Fibrinolytic Enzyme. We next asked what
the critical substrate for MMP9 is in kidney. Because fibrin
accumulated in MMP92/2 mice, we hypothesized that
MMP9 exerts a protective effect in the development of
glomerular lesions by degrading fibrin. We performed
three sets of experiments to address this hypothesis.
First, we demonstrated that MMP9 degrades fibrin by fi-
brin zymography. SDS-PAGE gel of activated recombinant
mouse MMP9 loaded at different doses was applied to a fi-
brin gel (Fig. 6 A). The lytic zones corresponded to the mi-
gration of the active form of MMP9 with their intensity
proportional to the quantity of MMP9. When recombinant
human TIMP1, the natural MMP9 inhibitor, was incorpo-
rated in the fibrin gel, fibrinolysis was abolished. These re-
sults suggest that MMP9 is able to degrade fibrin in a dose-
dependent manner.
Second, we determined the sensitivity of fibrinogen and
fibrin chains to MMP9 proteolysis. MMP9 degraded the
Aa and Bb chains of fibrinogen, and this proteolytic effect
was inhibited by 1,10-phenanthroline, a zinc chelator (and
thus a metalloprotease inhibitor), but not by aprotinin, a
plasmin inhibitor (Fig. 6 B). Fibrinolytic products gener-
ated by plasmin were different since gg chains were de-
graded. As expected, plasmin proteolytic effect was inhib-
ited by aprotinin, but not by 1,10-phenanthroline (Fig. 6
C). The fibrin a chains and the a polymers were preferen-
tially degraded by MMP9. Doublets observed for gg and b
chains were most likely degradation products of a polymers
and a chains, but they might also result from partial degra-
dation of gg and b chains. Fibrin degradation did not occur
when 1,10-phenanthroline was added along with MMP9
(data not shown). Although fibrin pellets were washed ex-
tensively, we could not rule out a possible contamination
with plasminogen or plasminogen activators, tissue-type
plasminogen activator (tPA) and urokinase-type plasmino-
gen activator (uPA), since fibrin was prepared from plasma.
To verify that MMP9 directly cleaved fibrin and had no ef-
fect upstream on plasmin activation, we added aprotinin, a
plasmin inhibitor, to the incubation medium. The MMP9
degradation profile of fibrin was not altered by aprotinin
(Fig. 6 B), which indicated that MMP9 degraded fibrin di-
rectly.
Figure 5. IL-1b degradation and IL-10 production. (A) The amount of
IL-1b produced by glomeruli isolated from MMP91/1 and MMP92/2
mice 15 d after injection of anti-GBM antibody was estimated in a semi-
quantitative manner by Western blot analysis. The polyclonal anti–mouse
antibody yielded a single band with 100 ng recombinant mouse IL-1b
and two bands corresponding to the intact (17.5 kD) and degraded (14.5
kD) forms of IL-1b after incubation with activated recombinant mouse
MMP9 (IL-1b plus MMP9, middle). The specificity of these bands was
further assessed by incubating the membrane with the polyclonal anti-
body preincubated with an excess of IL-1b (Control antibody, right).
The intact and degraded forms of IL-1b were observed with the same in-
tensity in glomerular extracts (100 mg of total proteins) from MMP91/1
and MMP92/2 mice (left). (B) Quantitative analysis of the blots per-
formed with glomeruli isolated from MMP91/1 and MMP92/2 mice
15 d after injection of anti-GBM antibody. Note similar ratio of the two
bands in both groups of mice. (C) IL-10 production by glomeruli isolated
from MMP91/1 (hatched bars) and MMP92/2 (white bars), noninjected
mice (Control), or mice injected with anti-GBM antibody after 48 h, 7 d,
and 15 d. IL-10 production was significantly increased in both groups of
injected mice compared with their respective noninjected controls (P ,
0.01), but it was not significantly different between MMP92/2 and
MMP91/1 glomeruli at the different time points after injection. Values
are mean 6 SEM.799 Lelongt et al.
Finally, we showed that MMP9 could degrade fibrin in
situ. Incubation with activated recombinant mouse MMP9
of serial kidney cryosections from MMP92/2 mice killed
15 d after anti-GBM injection strongly reduced glomerular
fibrin deposition. This effect was abolished by 1,10-
phenanthroline (Fig. 7 A). To further demonstrate that
fibrin is a physiological substrate for MMP9 in vivo, we in-
cubated serial kidney sections with control gelatinase sub-
strate buffer (Fig. 7 B, 1) or glomerular extracts from
injected MMP91/1 mice treated either with plasmin inhib-
itor (Fig. 7 B, 2) or with plasmin and metalloproteinase in-
hibitor (Fig. 7 B, 3). Results show that glomerular fibrin
deposits can be cleaved by glomerular extracts when plas-
min is inhibited (Fig. 7 B, 2) and that this fibrinolytic activ-
ity is due to MMP9 since it is abolished in the presence of
phenanthroline (Fig. 7 B, 3), or when MMP91/1 glomeru-
lar extracts are replaced by MMP92/2 glomerular extracts
(Fig. 7 B, 4). Fibrin deposits completely disappeared when
plasmin activity was not blocked in sections incubated with
untreated glomerular extracts from MMP91/1 injected
mice (data not shown). These results demonstrate that
MMP9, like plasmin, contributes to fibrinolytic activity in
this model.
Discussion
Our data show that MMP9 is an important regulator of
renal function. We took advantage of the availability of
MMP92/2 mice (8) to analyze their renal phenotype in an
accelerated model of crescentic proliferative glomerulone-
phritis. MMP92/2 mice developed a more severe form of
anti-GBM nephritis than their wild-type mates. We pro-
vide the first evidence that MMP9 protects mice from cres-
centic proliferative glomerulonephritis (a model where fi-
brin deposits play a major role) through its fibrinolytic
activity.
We have previously shown that MMP9 is produced at
the first stage of kidney embryogenesis in vivo and is re-
Figure 6. Fibrinolytic activity of MMP9. (A) Zymo-
gram performed on fibrin gel. 300 ng, 150 ng, and 50 ng of
activated recombinant mouse MMP9 were loaded on 8%
SDS polyacrylamide gels that were applied to a fibrin gel.
Note a lytic band at the expected molecular size for the ac-
tive form of MMP9. Its intensity was proportional to the
quantity of MMP9. Lytic activity was inhibited when 10
mg/ml of recombinant human TIMP1 was incorporated in
the fibrin gel (300 ng plus TIMP1). (B) SDS-PAGE analy-
sis of 10 mg fibrinogen and 3 mg fibrin after a 24- or 72-h
incubation, respectively, with 300 ng of activated recombi-
nant mouse MMP9 alone or in the presence of a metallo-
protease inhibitor (1 mM 1,10-phenanthroline [Phen.]) or
of a plasmin inhibitor (8 U aprotinin [Aprot.]). Note that
MMP9 degraded Aa and Bb chains of fibrinogen (com-
pare MMP9 with Control), and that degradation was in-
hibited by 1,10-phenanthroline (MMP9 1 Phen. versus
MMP9) but not by aprotinin (MMP9 1 Aprot. versus
MMP9). The a chain and a polymers of fibrin chains were
preferentially degraded by MMP9 (MMP9 versus Control).
Degradation was not inhibited by aprotinin (MMP9 1
Aprot. versus MMP9). The minor band forming a doublet
with  gg and  b chains, respectively, in the presence of
MMP9 could result from partial degradation of these chains
by MMP9 and/or from degradation of a chain and a poly-
mers. (C) SDS-PAGE analysis of 10 mg fibrinogen after a
24-h incubation with 10 mU of plasmin alone or in the
presence of a metalloprotease inhibitor (1 mM 1,10-
phenanthroline [Phen.]) or of a plasmin inhibitor (8 U
aprotinin [Aprot.]). Note that plasmin degraded the three
chains of fibrinogen, and that degradation was inhibited by
aprotinin (Plasmin 1 Aprot versus Plasmin) but not by
1,10-phenanthroline (Plasmin 1 Phen. versus Plasmin).800 MMP9-deficient Mice Phenotype and MMP9 Fibrinolytic Activity
quired for branching morphogenesis in vitro (3). We pos-
tulated that MMP9 deficiency in mice would impede
kidney growth. However, MMP92/2 mice are viable, sug-
gesting the absence of major kidney defects. The histologi-
cal appearance, immunohistochemical analysis of several
basement membrane components, and renal function of
these mice were normal up to 5 mo (15). We confirmed
these results in MMP92/2 and control mice up to 6 mo of
age (data not shown).
MMP9 expression is increased in various human and ex-
perimental models of nephropathies (reference 6; for a re-
view, see reference 7). To establish its role, we investigated
the susceptibility of MMP92/2 mice to crescentic prolifera-
tive glomerulonephritis in an accelerated model of anti-
GBM disease. By analogy to the results observed in bullous
pemphigoid (20), where the initial lesion affects the base-
ment membrane as in anti-GBM nephritis, we hypothe-
sized that MMP92/2 mice would be protected from the
development of glomerular lesions. In the murine model of
bullous pemphigoid, MMP92/2 mice showed deposition of
injected antibodies to the membrane and neutrophil
recruitment to the skin but epidermal blistering does not
develop (20). This defect owes to a lack of inactivation of
a1-proteinase inhibitor by MMP9, which does not allow
neutrophil elastase to function (21). Unexpectedly, how-
ever, MMP9 deficiency was associated with functional and
histological exacerbation of glomerular injury. MMP92/2
mice showed a significantly increased propensity to form
crescents. Crescents result from accumulation, in the uri-
nary space, of fibrin that is chemotactic for macrophages
and favors proliferation of glomerular parietal epithelial
cells (9, 22). Indeed, we observed a decreased clearance or
degradation of fibrin because of lack of MMP9 activity in
MMP92/2 mice. The increased renal impairment, fibrin
deposition, and crescent formation in those mice suggest
that MMP9 plays a important role in protecting glomeruli
against injury.
The extent of immune response to the exogenous anti-
gen could not account for the severity of injury since circu-
lating levels of mouse anti–sheep IgG antibodies and anti-
body deposition to the basement membrane were similar in
MMP92/2 and MMP91/1 mice. We observed a slight but
not significant increase in the number of intra- and peri-
glomerular macrophages. Results observed in the literature
vary from one system to another. Macrophage infiltration
and collagen accumulation in the heart-infarcted region of
MMP92/2 mice were decreased in an experimental model
of myocardial infarction (23), but were not modified in
young and adult MMP92/2 mice that were resistant to the
development of experimental autoimmune encephalomy-
elitis (24). Macrophages have a pivotal role in the transition
between inflammation and repair through the balanced se-
cretion of pro- and antiinflammatory cytokines. Although
the number of glomerular and periglomerular macrophages
was not significantly altered by MMP9 deficiency, it was
still possible that macrophage phenotype was altered. We
analyzed IL-1b and IL-10 for two reasons. First, IL-1b en-
hances glomerular fibrin deposition and crescent formation
in this model (16) whereas IL-10 has a protective effect
(18). Second, MMP9 degrades IL-1b in vitro (17) and in-
creases IL-10 production in a model of skin contact hyper-
sensitivity (19). We hypothesized that IL-1b degradation or
IL-10 production could be altered in MMP92/2 mice with
anti-GBM proliferative glomerulonephritis. However, we
could not find significant differences in the production or
degradation of these cytokines that could account for the
increment of glomerular lesions.
The exacerbation of glomerular injury observed in
MMP92/2 mice was reminiscent of the findings observed
in tPA- or plasminogen-deficient mice (25) after induction
Figure 7. Fibrinolytic activity of MMP9 on tissue sec-
tions. (A) In situ degradation of glomerular fibrin deposits
by MMP9. Serial kidney cryosections from MMP92/2
mice killed 15 d after anti-GBM injection were incu-
bated with incubation medium (Control), 300 ng of acti-
vated recombinant mouse MMP9 alone (MMP9), or
with 1,10-phenanthroline (1 mM 1,10-phenanthroline
[MMP9  1  Phenan.]) before fibrin detection by immuno-
fluorescence. Note that MMP9 strongly reduced inten-
sity of glomerular fibrin deposits, but phenanthroline pre-
vented this effect. Bar, 400 mm. (B) In situ degradation of
glomerular fibrin deposits by glomerular extracts. 1, ge-
latinase substrate buffer; 2, glomerular extracts from 1/1
control mice (15 d after anti-GBM injection) treated with
plasmin inhibitor (1,000 U/ml aprotinin); 3, glomerular
extracts from 1/1 control mice (15 d after anti-GBM
injection) treated with plasmin inhibitor and metallopro-
teinase inhibitor (1 mM 1,10-phenanthroline); 4, glo-
merular extracts from MMP92/2 mice (15 d after anti-
GBM injection) treated with plasmin inhibitor. Fibrin
deposits on glomerular sections were detected by immu-
nofluorescence. Note that glomerular extracts containing
MMP9 activity strongly reduced the intensity of glomer-
ular fibrin deposits in the absence of plasmin activity (2).
This effect was abolished when MMP9 activity was in-
hibited (3) or absent (4). Bar, 400 mm.801 Lelongt et al.
of a similar crescentic proliferative glomerulonephritis.
tPA-deficient mice and plasminogen-deficient mice, in-
deed, showed severe functional and histological exacerba-
tion of glomerular injury, whereas neither uPA nor uPA
receptor deficiency affected the expression of glomerulone-
phritis. We first verified, by fibrin zymography on serum
and glomerular tissues, that tPA and uPA enzymatic activi-
ties were not downregulated during the course of glomeru-
lonephritis in MMP92/2 mice (data not shown). We then
hypothesized that MMP9 itself could be involved in fibrino-
lysis. Other members of the MMP family, MT1-MMP
(MMP14), stromelysin-1 (MMP3), collagenase-1 (MMP1)
MMP2 (26), and MT4-MMP (MMP17) (11) are able to
degrade fibrinogen and fibrin in vitro. Our data show that
MMP9 not only can degrade fibrin in vitro, but also is re-
sponsible for its degradation in vivo during the course of
glomerulonephritis. We found that MMP9 produced lysis
bands in fibrin gel, degraded the Aa and Bb chains of fi-
brinogen and the a chains and a polymers of fibrin, and
partially solubilized in situ glomerular fibrin deposits in
mice with anti-GBM proliferative glomerulonephritis. The
action of MMP9 on fibrin was direct, and not plasmin me-
diated, since aprotinin, a plasmin inhibitor, does not pre-
vent MMP9-induced fibrin degradation. MMP9 cleaves
the same fibrin and fibrinogen chains as MT1-MMP, sug-
gesting a similar fibrinolytic effect of these enzymes (26). In
addition, we show for the first time that the fibrinolytic ac-
tivity of MMP9 is critical in vivo. On the basis of the re-
sults obtained by Kitching et al. (25) and our own data, we
anticipate that the severity of anti-GBM nephritis would be
even more greater in double tPA-MMP9 knockout mice.
MMP9 was first described because of its ability to cleave
extracellular matrix macromolecules including type IV and
V collagens and denatured collagens (gelatin) in vitro (for a
review, see reference 1). Subsequently, MMP9 has been
shown to cleave other extracellular matrix substrates, such
as BP 180, and nonmatrix components, like serpins, and to
activate TGF-b in vitro (for reviews, see references 1, 21,
27). Thus, our data add to the increasing list of MMP9 sub-
strates that are not conventional matrix components. They
also show that fibrin is a critical substrate for MMP9 in
vivo. Only one substrate, a1-proteinase inhibitor, had been
previously identified as an MMP9 substrate in vivo (21).
In conclusion, our results show that MMP9 contributes
to the breakdown of fibrin caps observed in glomeruli dur-
ing the course of glomerulonephritis. Since fibrin is an im-
portant mediator of glomerular injury favoring the prolifer-
ation of epithelial cells (leading to crescent formation) and
subsequently the invasion of fibroblasts, the fibrinolytic ef-
fect of MMP9 can partially account for its antifibrotic
properties.
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